$192 Million is the total value of Altium Capital Management LP's 72 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 3.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS INC | $10,049,276 | -10.4% | 1,347,088 | 0.0% | 5.24% | -38.3% | ||
| XENE | XENON PHARMACEUTICALS INC | $7,788,480 | -11.3% | 228,000 | 0.0% | 4.06% | -38.9% | |
| MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $5,016,000 | +11.8% | 88,000 | 0.0% | 2.62% | -23.0% | ||
| COGT | COGENT BIOSCIENCES INC | $2,291,250 | -17.7% | 235,000 | 0.0% | 1.20% | -43.3% | |
| JASPER THERAPEUTICS INC | $2,007,600 | -48.9% | 2,868,000 | 0.0% | 1.05% | -64.8% | ||
| KPTI | KARYOPHARM THERAPEUTICS INC | $991,600 | -25.1% | 740,000 | 0.0% | 0.52% | -48.5% | |
| DOUBLEDOWN INTERACTIVE CO LTads | $516,228 | -11.4% | 60,876 | 0.0% | 0.27% | -39.0% | ||
| WEARABLE DEVICES LTD*w exp 09/14/202 | $168,474 | -40.3% | 1,411,600 | 0.0% | 0.09% | -58.9% | ||
| DIRECT DIGITAL HOLDINGS INC*w exp 02/15/202 | $108,018 | +0.0% | 180,000 | 0.0% | 0.06% | -31.7% | ||
| MBTCR | NOCTURNE ACQUISITION CORPright 12/26/2025 | $78,250 | +25.1% | 500,000 | 0.0% | 0.04% | -12.8% | |
| NEXGEL INC*w exp 12/01/202 | $76,500 | -21.3% | 225,000 | 0.0% | 0.04% | -45.9% | ||
| CINGULATE INC*w exp 12/10/202 | $44,550 | -21.4% | 270,000 | 0.0% | 0.02% | -46.5% | ||
| ONFOLIO HOLDINGS INC*w exp 01/02/202 | $26,680 | -33.3% | 200,000 | 0.0% | 0.01% | -53.3% | ||
| PEPPERLIME HEALTH ACQUSTN CO*w exp 10/01/202 | $26,093 | +210.0% | 367,500 | 0.0% | 0.01% | +133.3% | ||
| JEFFS BRANDS LTD*w exp 08/26/202 | $21,394 | -61.6% | 480,770 | 0.0% | 0.01% | -73.8% | ||
| NLSPW | NLS PHARMACEUTICS LTD*w exp 02/02/202 | $21,040 | -1.7% | 200,000 | 0.0% | 0.01% | -31.2% | |
| PROSOMNUS INC*w exp 04/20/202 | $10,500 | -13.0% | 150,000 | 0.0% | 0.01% | -44.4% | ||
| CEA INDUSTRIES INC*w exp 02/11/202 | $9,200 | -30.2% | 250,000 | 0.0% | 0.01% | -50.0% | ||
| HARBOR CUSTOM DEVELOPMENT IN*w exp 10/07/202 | $6,435 | +12.5% | 650,000 | 0.0% | 0.00% | -25.0% | ||
| TG VENTURE ACQUISITION CORP*w exp 08/15/202 | $6,400 | +42.2% | 200,000 | 0.0% | 0.00% | 0.0% | ||
| WESTERN ACQSTN VENTURES CORP*w exp 09/01/202 | $3,210 | -47.3% | 100,000 | 0.0% | 0.00% | -60.0% | ||
| CHAVANT CAPITAL ACQUISITN CO*w exp 99/99/999 | $4,380 | -32.1% | 150,000 | 0.0% | 0.00% | -60.0% | ||
| SURROZEN INC*w exp 08/01/203 | $3,380 | -25.5% | 82,233 | 0.0% | 0.00% | -33.3% | ||
| COLISEUM ACQUISITION CORP*w exp 08/22/202 | $3,612 | -15.0% | 28,333 | 0.0% | 0.00% | -33.3% | ||
| HCDIW | HARBOR CUSTOM DEVELOPMENT IN*w exp 05/09/202 | $4,500 | +7.1% | 600,000 | 0.0% | 0.00% | -33.3% | |
| DIGITAL HEALTH ACQUISITION C*w exp 11/02/202 | $3,315 | -66.8% | 150,000 | 0.0% | 0.00% | -75.0% | ||
| OPY ACQUISITION CORP I*w exp 09/22/202 | $1,385 | -67.5% | 50,000 | 0.0% | 0.00% | -66.7% | ||
| NEXALIN TECHNOLOGY INC*w exp 09/15/202 | $2,625 | -77.3% | 105,000 | 0.0% | 0.00% | -88.9% | ||
| SELINA HOSPITALITY PLC*w exp 10/27/202 | $1,420 | -67.2% | 101,439 | 0.0% | 0.00% | -66.7% | ||
| TC BIOPHARM HOLDINGS PLC*w exp 02/08/202 | $393 | -51.4% | 18,823 | 0.0% | 0.00% | -100.0% | ||
| RELATIVITY ACQUISITION CORP*w exp 12/15/202 | $0 | – | 100,000 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.